Table 2.
Number of patients, events, follow-up time, incidence rates, and hazard ratios for anuria in an IPTW cohort
| Cohort | Analysis | Exposure group | N | Number of events | Follow-up time (years) | Incidence rate (per 100 person-years) | Hazard ratio (95% CI) | |
|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Median | |||||||
| Full cohort | ITT | ACEI/ARB | 389 | 121 | 1.05 ± 0.89 | 0.81 | 29.6 | 0.86 (0.73, 1.02) |
| Non-user | 497 | 159 | 0.87 ± 0.82 | 0.62 | 36.9 | |||
| Full cohort | AT | ACEI/ARB | 389 | 53 | 0.35 ± 0.37 | 0.24 | 0.66 (0.51, 0.84) | |
| Non-user | 497 | 91 | 0.30 ± 0.33 | 0.19 | ||||
| Baseline rGFR ≤20 ml/min | ITT | ACEI/ARB | 379 | 118 | 1.05 ± 0.89 | 0.80 | 0.87 (0.74, 1.03) | |
| Non-user | 485 | 156 | 0.88 ± 0.82 | 0.62 | ||||
| ≥1 year on PD cohort | ITT | ACEI/ARB | 203 | 59 | 0.93 ± 0.80a | 0.71a | 0.98 (0.76, 1.27) | |
| Non-user | 209 | 58 | 0.85 ± 0.78a | 0.63a | ||||
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin-II receptor blocker, AT as treated, CI confidence interval, IPTW inverse probability of treatment weighted, ITT intention to treat, rGFR residual glomerular filtration rate, SD standard deviation
aNote that follow-up for the ≥1 year on PD cohort began on day 365 of dialysis whereas in the other analyses follow-up began on day 90 of dialysis. Thus, patients in the ≥1 year on PD cohort were followed on average until day 690 of dialysis whereas patients in the unadjusted ITT analysis of the full cohort were followed on average until day 436 of dialysis